Long‐term safety and tolerability of hyaluronidase‐facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE‐CIDP 3 trial
ADVANCE-CIDP 3 demonstrated favorable fSCIG long-term safety and tolerability consistent with its established safety profile, and a low relapse rate, supporting use as maintenance CIDP treatment.
Authors
- Shabbir Hasan
- Ivana Basta (ORCID: https://orcid.org/0000-0002-4786-8339)
- Colin Anderson‐Smits (ORCID: https://orcid.org/0000-0002-2734-6154)
- Robert D. M. Hadden (ORCID: https://orcid.org/0000-0002-9702-0256)
- Konrad Rejdak (ORCID: https://orcid.org/0000-0002-7019-6681)
- Kimberly Duff (ORCID: https://orcid.org/0009-0000-3657-5293)
- Henning Andersen
- Vera Bril (ORCID: https://orcid.org/0000-0002-5805-4883)
- Hakan Ay (ORCID: https://orcid.org/0000-0002-9146-0218)
- Erin Greco
Institutions
- Medical University of Lublin (PL)
- University Health Network (CA)
- King's College London (GB)
- University of Toronto (CA)
- Aarhus University Hospital (DK)
- University of Belgrade (RS)
- Takeda (United States) (US)
- King's College Hospital (GB)
Publication Details
- Journal
- Journal of the Peripheral Nervous System
- Published
- 2024-11-11
- DOI
- https://doi.org/10.1111/jns.12672
- Citations
- 8
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.95